IBRX ImmunityBio, Inc.: institutional ownership and insider trading
436 funds reported holding $2.07B of ImmunityBio, Inc. in their latest 13F filings; in Q2 2026 funds net bought $196M, with 59 new positions and 45 funds selling out; over the last 12 months insiders bought $0 and sold $9.51M on the open market; over its last four quarters it reported revenue of $166M and net income of −$992M.
IBRX revenue and earnings
- Quarter ended Jun 30, 2026: revenue $51.2M, net income −$230M, EPS -0.22
- Quarter ended Mar 31, 2026: revenue $44.2M, net income −$633M, EPS -0.62
- Quarter ended Dec 31, 2025: revenue $38.3M, net income −$62.0M, EPS -0.06
- Quarter ended Sep 30, 2025: revenue $32.1M, net income −$67.3M, EPS -0.07
Famous investors holding IBRX
- Two Sigma (Two Sigma Investments): $97.2M, 0.1% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $101M, 0.1% of the portfolio
- Izzy Englander (Millennium Management): $48.9M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $49.7M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $9.01M, 0.0% of the portfolio
Largest institutional holders of IBRX
- BlackRock, Inc. (BLK) — $298M
- STATE STREET CORP (STT, STT-PG) — $187M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $156M
- VANGUARD CAPITAL MANAGEMENT LLC — $137M
- D. E. Shaw & Co., Inc. — $101M
- TWO SIGMA INVESTMENTS, LP — $97.2M
- GEODE CAPITAL MANAGEMENT, LLC — $86.2M
- SUSQUEHANNA INTERNATIONAL GROUP, LLP — $73.3M
- VANGUARD GROUP INC — $64.9M
- CITADEL ADVISORS LLC — $49.7M
Recent IBRX insider trades
- Oct 5, 2026: Simon Barry J. sold 25,000 shares ($269K)
- Oct 2, 2026: Cohen Cheryl sold 81,056 shares ($851K)
- Jul 2, 2026: Cohen Cheryl sold 131,210 shares ($1.25M)
- Jul 1, 2026: Selecky Christobel sold 159,478 shares ($1.44M)
Members of Congress trading IBRX
- Sep 30, 2026: Lisa C. McClain bought $1.00K–$15.0K
- Sep 28, 2026: Lisa C. McClain bought $1.00K–$15.0K
5%+ owners
- Patrick Soon-Shiong: 64.8% (Schedule 13D/A, filed Aug 6, 2026)